J&J Proposes $5.5 Billion Settlement to Resolve Decades-Old Talc Lawsuits

Healthcare giant Johnson & Johnson (J&J) has proposed a settlement of up to $5.5 billion to resolve tens of thousands of lawsuits alleging that its talc-based baby powder caused ovarian cancer and mesothelioma. The proposed deal represents a major milestone in the company's multi-year effort to put an end to one of the most complex and costly product-liability disputes in corporate history. If approved by the claimants, the multi-billion-dollar agreement would consolidate and resolve the vast majority of pending and future talc-related injury claims against the company in the United States.

For more than a decade, J&J has defended itself against claims that its cosmetic talc products contained trace amounts of asbestos, a known carcinogen. Despite the growing mountain of lawsuits, the company has consistently maintained that its products are safe, asbestos-free, and do not cause cancer, pointing to decades of independent clinical studies. However, amid declining sales, reputational pressure, and mounting legal defense costs, J&J transitioned its global product line entirely to cornstarch-based baby powder, phasing out talc altogether by 2023.

To manage the financial fallout, J&J has repeatedly attempted to resolve the liabilities through a controversial legal maneuver, transferring its talc liabilities to a subsidiary, which then files for Chapter 11 bankruptcy protection.

• The Corporate Position: "Resolving these claims through a structured settlement is in the best interest of all parties," the company's litigation team noted in a statement. "It provides claimants with fair, timely compensation while giving our shareholders the finality and predictability they deserve, rather than leaving these complex scientific questions to the unpredictability of jury trials."
• The Plaintiffs' Stance: While some plaintiffs' attorneys have welcomed the offer as a pragmatic end to the exhausting legal saga, others argue the sum is insufficient to cover the long-term healthcare costs and suffering of the victims.

The success of the proposed $5.5 billion settlement hinges on securing a 75% approval rate from the claimants, a threshold required under U.S. bankruptcy law to finalize a prepackaged restructuring plan. If this threshold is met, the plan will go before a federal bankruptcy judge for final confirmation. A successful resolution would allow J&J to permanently wall off future talc litigation, though a failure to secure the necessary votes would force the company back into the tort system, where it faces the risk of unpredictable, multi-million-dollar jury verdicts.